Regarding the pre-clinical data, the number of BC cell lines remains limited (2 IBC and 2 nIBC) and does not allow a complete representation of all molecular subtypes; analysis of more cell lines of each molecular subtype is warranted, as well as the deployment and analysis of in vivo animal models that are better adapted than cell lines to investigate the aggressiveness and metastatic properties related to MARCKS. This evidence concerns the gene MARCKS and breast cancer.